Initiation of Medication in Treating Opioid Use Disorder.
|
|
- Wilfred Oliver
- 6 years ago
- Views:
Transcription
1 Initiation of Medication in Treating Opioid Use Disorder. Colleen T. LaBelle MSN RN-BC CARN Program Director STATE OBAT B Nurse Manager Boston Medical Center OBAT Executive Director MA IntNSA *Images used for educational purposes only. All copyrights belong to image owners*
2 Objectives Identify the clinically relevant pharmacological characteristics of agonist and antagonist treatments Describe the induction process Identify the difference between short- vs. long-acting opioids and induction Describe how to induce opioid naive patient
3 Objectives Identify the clinically relevant pharmacological characteristics of agonist and antagonist treatments Describe the induction process Identify the difference between short- vs. long-acting opioids and induction Describe how to induce opioid naive patient
4 Function at Receptors: Full Opioid Agonists Mu receptor Full agonist binding activates the mu receptor is highly reinforcing is the most misused opioid type includes heroin, codeine, & others Adapted from NIDA, Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition)
5 Function at Receptors: Partial Opioid Agonists Mu receptor Partial agonist binding elicits muted receptor activation is relatively less reinforcing is a less misused opioid type includes buprenorphine Adapted from NIDA, Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition)
6 Function at Receptors: Opioid Agonists Mu receptor Antagonist binding occupies without activating is not reinforcing blocks opioid agonist types includes naloxone and naltrexone Adapted from NIDA, Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition)
7 Opioid Effect How Does Buprenorphine Work? (1) Full Agonist (Methadone) Partial Agonist (Buprenorphine) Log Dose Antagonist (Naloxone)
8 How Does Buprenorphine Work? (2) AFFINITY is the strength with which a drug physically binds to a receptor Buprenorphine has strong affinity; will displace full mu receptor agonists like heroin and methadone Synapse Receptor binding strength (strong or weak), is NOT the same as receptor activation H B B H Buprenorphine affinity is higher, therefore full agonist is displaced Mu receptor Adapted from
9 How Does Buprenorphine Work? (3) DISSOCIATION is the speed (slow or fast) of disengagement, or uncoupling, of a drug from the receptor Buprenorphine dissociates slowly Therefore buprenorphine stays on the receptor a long time and blocks heroin, methadone, and other opioids from binding to those receptors Synapse H B B H Buprenorphine dissociates slowly, so full agonist has reduced binding Mu receptor Adapted from
10 How Does Buprenorphine Work? (4) Ceiling effect on opioid effects High affinity for opioid receptor Slow dissociation from opioid receptor Formulated with naloxone Naloxone blocks opiate effect if injected Naloxone has low bioavailability if taking orally Gunderson, 2006
11 Formulations Generic sublingual (SL) buprenorphine tablets and generic SL bup/nlx Buprenorphine and buprenorphine/naloxone film Buccal film: cheek Buprenorphine patch: pain only New formula buprenorphine/naloxon: different dosage Implantable buprenorphine Buprenorphine sublingual film ASAM, 2015
12 Objectives Identify the clinically relevant pharmacological characteristics of agonist and antagonist treatments Describe the induction process Identify the difference between short- vs. long-acting opioids and induction Describe how to induce opioid naive patient
13 Planning for Induction Boston Medical Center 2016, P&P Build a Relationship. Build Trust: Early stages of withdrawal prior to induction Review with patient ahead of time: Usage history, withdrawal, last use Reinforcing the goal to improve symptoms Help them feel better Short-acting, long-acting What did they last use?
14 Buprenorphine Induction: Office Logistics (1) Boston Medical Center 2016, P&P Lee et al. (2009). Home Buprenorphine/Naloxone Induction in Primary Care
15 Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Daniel P. Alford, MD, MPH; Colleen T. LaBelle, RN; Natalie Kretsch, BA; Alexis Bergeron, MPH, LCSW; Michael Winter, MPH; Michael Botticelli, Med; Jeffrey H. Samet, MD, MA, MPH Collaborative care model at BMC utilizing nurse care managers working with physicians to deliver outpatient opioid treatment with buprenorphine More recently dubbed the Massachusetts Model Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH. Arch Intern Med. 2011;171:
16 How to Prevent Precipitated Withdrawal (1)
17 How to Prevent Precipitated Withdrawal (2) Withdrawal more likely when: Level of physical dependence is high Short time since last opioid use (shortvs long-acting opioids) Initial dose of buprenorphine too high Prevention: Administer 1st buprenorphine dose when objective signs of withdrawal are present ASAM, 2015; PCSS 2013
18 A Case Study in Induction Part 1
19 Buprenorphine Induction - Day 1 Instruct the patient to abstain from any opioid use prior to induction to avoid precipitated withdrawal: 8 12 hours for short-acting opioids 24 hours for sustained-release opioid medications 36 or > hours for methadone; assessment is critical Gunderson; PCSS; ASAM
20 Buprenorphine Induction - Day 2 If patient is not in opioid withdrawal at time of arrival in office: Assess last opioid use Consider returning another day, or wait and reassess for withdrawal. Ask specifically about last use (heroin, fentanyl, methadone, oxycodone) Short- vs long-term opioids Methadone requires more time Avoid precipitating withdrawal Boston Medical Center 2016 P&P
21 Case Study (1) John M., a 33-year-old tax accountant, presents to your office anxious to start buprenorphine and to be done with using. He has spent the last 4 years injecting 1 2 gms of heroin a day. His life has begun to spin out of control and his fiancé is onto him that something is not right, but she doesn t know he has an OUD.
22 Case Study (2) He has come to all his appointments, had urine screens and blood work done, and set up counseling. He is in the waiting room one hour before the clinic opens waiting to be seen. Presents to the visit anxious to get started, he is so excited that this day is finally here: Reports last use at 6 pm the night before, it is 9:30am. I am ready to put this life behind me.
23 Case Study (3) The nurse performs an assessment using the Clinical Opioid Withdrawal (COW) scale and rates him a 9, and he last used 15 ½ hours ago. During assessment, patient reports GI distress, joint pain, restlessness, sweating, and anxiety. On observation - pulse 120, patient shifting around in his seat, trouble sitting still.
24 Case Study: Questions to Consider Is this patient ready for induction? Should you do anything further prior to beginning induction? Is there any harm in starting the induction?
25 Return to Case Study: Induction (1) Presents to the visit anxious to get started, he is so excited that this day is finally here: I am ready to put this life behind me. Reports last use at 6 pm the night before, it is 9:30am. The nurse performs an assessment using the COW scale rates him a 9, and last used 15 ½ hours ago. During assessment, patient reports GI distress, joint pain, restlessness, sweating, and anxiety. On observation - pulse 120, patient shifting around in his seat, trouble sitting still.
26 Return to Case Study: Induction (2) Is John M. ready for induction? Presents to the visit anxious to get started, he is so excited that this day is finally here: I am ready to put this life behind me. Reports last use at 6 pm the night before, it is 9:30am. The nurse performs an assessment using the COW scale rates him a 9, and last used 15 ½ hours ago. During assessment, patient reports GI distress, joint pain, restlessness, sweating, and anxiety. On observation - pulse 120, patient shifting around in his seat, trouble sitting still.
27 Buprenorphine Induction - Day 1 First dose: 2 to 4 mg SL buprenorphine/naloxone Monitor in office for 1+ hours after first dose Opioid withdrawal symptoms should improve minutes after the first dose Better, worse, or the same? If opioid withdrawal subsides but then reappears, re-dose every 2 3 hours Aim for a dose of 8 12 mg in the first 24 hours Boston Medical Center P&P 2016
28 Wesson, 2003
29 Buprenorphine Induction - Day 1 If opioid withdrawal appears: may have precipitated withdrawal Greatest severity precipitated withdrawal: First few hours (1 4) after a dose Decreasing symptoms over subsequent hours PCSS Guidelines
30 Buprenorphine Induction - Day 1 (Continued) If precipitate withdrawal: Continue dosing, provide agonist effect, suppress withdrawal OR Stop induction, provide symptomatic treatments, and have the patient return the next day Latter - risk losing the patient, the first option is often preferred
31 Dailymed.nlm.nih.gov Buprenorphine Induction - Patient Education Sublingual tablets/film held under tongue until dissolved Start with a moist mouth Avoid acidic drinks (coffee or fruit juice) No smoking immediately before or after No talking during administration Keep tablet or film under tongue or buccal mucosa Do not swallow until entire tablet or film dissolves PCSS, 2006
32 A Case Study in Induction Part 2
33 Clinical Opioid Withdrawal Scale (COWS) Recovery.org Total Score: 5 12 Mild Moderate Moderately Severe >36 Severe Aim for Score: 8 10 Wesson, 2003
34 Return to Case Study: Induction (1) Is John M. ready for induction? Presents to the visit anxious to get started, he is so excited that this day is finally here: I am ready to put this life behind me. Reports last use at 6 pm the night before, it is 9:30am. The nurse performs an assessment using the COW scale rates him a 9, and last used 15 ½ hours ago. During assessment, patient reports GI distress, joint pain, restlessness, sweating, and anxiety. On observation - pulse 120, patient shifting around in his seat, trouble sitting still.
35 Return to Case Study: Induction (2) Is John M. ready for induction? Should you do anything further prior to beginning induction? Is there any harm in starting the induction?
36 Wesson, 2003 Opioid Withdrawal Assessment Hours after use Grade Symptoms / Signs Anxiety, Drug Craving What symptoms do you see? Yawning, Sweating, Runny nose, Tearing eyes, Restlessness Insomnia Dilated pupils, Gooseflesh, Muscle twitching & shaking, Muscle & Joint aches, Loss of appetite Nausea, extreme restlessness, elevated blood pressure, Heart rate > 100, Fever Vomiting / dehydration, Diarrhea, Abdominal cramps, Curled-up body position Clinical Opiate Withdrawal Scale (COWS): pulse, sweating, restlessness & anxiety, pupil size, aches, runny nose & tearing, GI sx, tremor, yawning, gooseflesh (score 5-12 mild, mod, mod sev, severe)
37 Timing of Induction: Short-Acting Opioids Abstain 8 12 hours (mild withdrawal) If not in documented withdrawal: Review/assess history Assess, support, and wait What did you use in the last 24 hours? Ask specifically: methadone, oxycontin, heroin, fentanyl? Urine testing prior to induction if possible PCSS, 2006
38 Return to Case: Induction (1) John M., a 33-year-old tax accountant, presents to your office anxious to start buprenorphine and to be done with using. He has spent the last 4 years injecting 1 2 gms of heroin a day. His life has begun to spin out of control and his fiancé is onto him that something is not right, but she doesn t know he has a OUD.
39 Return to Case Study: Induction (2) Is John M. ready for induction? Presents to the visit anxious to get started, he is so excited that this day is finally here: I am ready to put this life behind me. Reports last use at 6 pm the night before, it is 9:30am. The nurse performs an assessment using the COW scale rates him a 9, and last used 15 ½ hours ago. During assessment, patient reports GI distress, joint pain, restlessness, sweating, and anxiety. On observation - pulse 120, patient shifting around in his seat, trouble sitting still.
40 Return to Case Study: Induction (3) Is John M. ready for induction? Should you do anything further prior to beginning induction? Is there any harm in starting the induction??
41 Wesson, 2003 Opioid Withdrawal Assessment Hours after use Grade John, what did you use in the last 24 hours? 4 Symptoms / Signs Anxiety, Drug Craving What symptoms do you see? Yawning, Sweating, Runny nose, Tearing eyes, Restlessness Insomnia Dilated pupils, Gooseflesh, Muscle twitching & shaking, Muscle & Joint aches, Loss of appetite Nausea, extreme restlessness, elevated blood pressure, Heart rate > 100, Fever Vomiting / dehydration, Diarrhea, Abdominal cramps, Curled-up body position Clinical Opiate Withdrawal Scale (COWS): pulse, sweating, restlessness & anxiety, pupil size, aches, runny nose & tearing, GI sx, tremor, yawning, gooseflesh (score 5-12 mild, mod, mod sev, severe)
42 Return to Case Study: Induction (1) John reports: I wanted to be safe and to be done with everything so I bought some methadone and got rid of my works and contacts. Should you do anything further prior to beginning induction? Is there any harm in starting the induction?
43 Objectives Identify the clinically relevant pharmacological characteristics of agonist and antagonist treatments Describe the induction process Identify the difference between short- vs. long-acting opioids and induction Describe how to induce opioid naive patient
44 Short-Acting Opioids 8 to 12 hours Oxycodone (Percocet, crushed Oxycontin ) Hydrocodone (Vicodin ) Heroin Morphine
45 Theaddictionhotline.org Long-Acting Opioids: Oxycontin P.O.: 24+ hours Methadone: 48+ hours Much harder and longer process Patient and provider need to be engaged PCSS Gunderson
46 Timing of Induction: Long-Acting Opioids: PCSS
47 Timing of Induction: Long Acting Opioids Abstain for at least 48+ hours Assess for withdrawal Timing is often not a good indicator Need to assess symptoms Slow and steady PCSS
48 First Dose of Buprenorphine Patient in clinical opioid withdrawal Objective signs are key to making diagnosis (can be challenging) COWS > 8 12 Start with 2 4 mg sl Assess: minutes after dosing Ask: better, worse, or the same? ASAM, PCSS
49 Induction Continue to titrate until symptoms resolve Re-assess patient minutes after first dose Dose with 2 4 mg sl Reassess over the next few hours Stabilize day one around 8 mg or per your protocol and clinical assessment PCSS
50 Induction days 2 3 Assess symptoms Adjust dose accordingly: withdrawal symptoms decrease over-medicated Continue adjusting by 2 4 mg increments target dose of mg Resolution of craving and withdrawal
51 Determining the Best Dose Remember goals of treatment Relieve withdrawal symptoms Reduce craving Opioid blockade Achieving these should result in improved function Gunderson, ASAM
52 Methadone to Buprenorphine (1) Challenging transition Objective withdrawal: most important May take much longer than 36 hours Support, communication, support Back-up plan: can they return to methadone?
53 Buprenorphine/Naloxone Toxicity, Medscape Methadone to Buprenorphine (2) PCSS; ASAM Practice guidelines
54 Methadone to Buprenorphine (3) Primary Goal: Minimize risk of precipitated withdrawal, manage withdrawal Knowledgeable provider Communication: MMT and BUP provider Taper methadone 30 mg/d or <, hold for 1 2 weeks (ideal) Stop methadone for 2 3 days, COWS score > 12 Ensure patient supports, comfort meds, emergency numbers
55 Methadone to Buprenorphine (4) Day 3 off methadone, observed induction with bup/nlx 2/0.5 mg, up to 8 mg on day as symptoms dictate. Treat symptoms Seamless return to methadone, if needed Utilize inpatient detox, if possible, allows added supports
56 What is the Optimal Dose? Like most medications, the optimal dose is the lowest dose that maximizes function and minimizes side effect Most patients stabilize on 8 24 mg/day Narcotic blockade Rarely 32 mg with the highly tolerant patient
57 Objectives Identify the clinically relevant pharmacological characteristics of agonist and antagonist treatments Describe the induction process Identify the difference between short- vs. long-acting opioids and induction Describe how to induce opioid naive patient
58 Buprenorphine Induction: Procedure Patients not physically dependent on opioids For example: high risk for relapse i.e., released from prison First dose: Start low, go slow (2 mg buprenorphine) Monitor and reassess Gradually increase dose over days/weeks Support
59 Buprenorphine Induction: Goals Dose of buprenorphine at which the patient: Has no opioid withdrawal symptoms Discontinues use of opioids No cravings Has narcotic blockade Has minimal or no side effects
60 Induction: Not Physically Dependent on Opioids Examples: High risk for relapse to opioid use: Pre/post incarceration Environmental Life stressor Cravings
61 Induction: Not Physically Dependent on Opioids First dose: 2 mg SL buprenorphine Monitor after first dose Gradually increase dose ( +2 mg/day) over several days/week as needed Stabilize dose that eliminates craving; dose range 2 mg to 16 mg Go slow and low. Avoid relapse. Gunderson, ASAM, PCSS
62 Induction Summary Put systems in place prior to starting Provide ongoing education and support Do not assume anything: ask questions Good clinical assessment: trust your gut No harm in waiting it out Objective assessment vs subjective reports Go slow and low Ask for help Use mentors AHRQ, Gunderson
63
64 Additional Resources: Buprenorphine Methadone and Buprenorphine: Opioid Agonist Substitution Tapers Models of Buprenorphine Induction How-To Guide: How to Conduct Buprenorphine Induction - This resource covers several procedures and is printer-friendly, so the clinician can print out the sections of the process that are most useful. Boston Medical Center. (2016). OBAT Policy and Procedure Manual: Policies and Procedure manual of the Office Based Addiction Treatment Program for the Use of Buprenorphine and Naltrexone Formulations in the Treatment of Substance Use Disorders (available in the course s Additional Resources tab).
65 References (1) Alford DP, LaBelle CT, Richardson JM, O'Connell JJ, Hohl CA, Cheng DM, Samet JH Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. Feb;22(2): Casadonte PP, Sullivan MA American Society of Addiction Medicine. (2015). Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Buprenorphine induction. Providers clinical support system for medication assisted treatment, PCSS guidance. August 9, 2006 (Updated November 27, 2013). Available at Boston Medical Center. (2016). OBAT Policy and Procedure Manual: Policies and Procedure manual of the Office Based Addiction Treatment Program for the Use of Buprenorphine and Naltrexone Formulations in the Treatment of Substance Use Disorders
66 References (2) Chou R, Korthuis PT, Weimer M, Bougatsos C, Blazina I, Zakher B, Grusing S, Devine B, McCarty D. Medication-Assisted Treatment Models of Care for Opioid Use Disorder in Primary Care Settings. Technical Brief No. 28. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No I.) AHRQ Publication No. 16(17)-EHC039-EF. Rockville, MD: Agency for Healthcare Research and Quality. December Gunderson EW, Fiellin DA, Levin FR, et al Evaluation of a combined online and in person training in the use of buprenorphine. Subst Abuse.27: Gunderson EW, Fiellin DA Office-Based Maintenance Treatment of Opioid Dependence: How Does it Compare with Traditional Approaches? CNS Drugs.22(2):99-11
67 References (3) LaBelle CT, Choongheon h, Bergeron A, Samet JA.. Office Based Opioid Treatment with Buprenorphine (OBOT): Statewide Implementation of Massachusetts Collaborative Care Model in Community Health Centers. J Subst Abuse Treat. 2016; 60: Mintzer IL, Eisenberg M, Terra M, et al Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med.5: Netherland J, Botsko M, Egan J, et al Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat.36: Walley AY, Alperen JK, Cheng DM, et al Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med.23: Wesson D, Ling W The Clinical Opiate Withdrawal Scale (COWS) J Psychoactive Drugs. 35:253
68 Unit Resources Bup.Practice - Opioid Classification: Agonists, Partial Agonists, and Antagonists NIDA - Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition) The National Alliance of Advocates for Buprenorphine Treatment (naabt.org) - Thorough Technical Explanation of Burprenorphine NIDA Notes - Impacts of Drugs on Neurotransmission How to take SUBOXONE Film Boston Medical Center - Office Based Addiction Treatment Policy and Procedure Manual - Office Based Addiction Treatment Program for the Use of Buprenorphine and Naltrexone Formulations in the Treatment of Substance Use Disorders American Society of Addiction Medicine (ASAM) - National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use
69 Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience American Addiction Centers - Opiate Withdrawal Timelines, Symptoms and Treatment Clinical Opiate Withdrawal Scale (COWS) (pdf) Providers Clinical Support System for Medication Assisted Treatment, (PCSS-MAT) - Buprenorphine induction (pdf) Providers Clinical Support System for Medication Assisted Treatment, (PCSS-MAT) - Buprenorphine induction (pdf) American Society of Addiction Medicine (ASAM) - National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use Providers Clinical Support System for Medication Assisted Treatment, (PCSS-MAT) - Buprenorphine induction (pdf) Agency for Healthcare Research and Quality (AHRQ) Providers Clinical Support System (PCSS-MAT) - Mentoring
Disclosures. I have no disclosures or commercial interests to report
Colleen T. LaBelle, MSN, RN-BC,CARN Program Director, Office-Based Addiction Treatment Director, STATE OBAT Boston Medical Center Disclosures I have no disclosures or commercial interests to report Medication-Assisted
More informationColleen T. LaBelle, MSN, RN-BC,CARN Program Director, Office-Based Addiction Treatment Director, STATE OBAT Boston Medical Center
Colleen T. LaBelle, MSN, RN-BC,CARN Program Director, Office-Based Addiction Treatment Director, STATE OBAT Boston Medical Center Disclosures I have no disclosures or commercial interests to report Addiction
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationOpioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
More informationOpioids Research to Practice
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
More informationOpioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationMedications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More informationModule II Opioids 101 Opiate Opioid
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module II Opioids 101 Module II Goals of the Module This module reviews the following:! Opioid addiction and the brain!
More informationBuprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationOAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM
OAT Transitions - focus on microdosing Mark McLean MD MSc FRCPC CISAM DABAM Disclosures No pharmaceutical industry or other financial conflicts of interest Study Physician for research funded by Canadian
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationMETHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE
METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE Work with methadone clinic staff to coordinate the methadone taper, with the transition to buprenorphine/naloxone:
More informationOpioid Replacement Therapy
Opioid Replacement Therapy Matthew A. Felgus, MD mafelgus@wisc.edu 6333 Odana Rd, Suite 3, Madison, WI 53719 (608) 257-1581 Board Certified in Addiction Medicine Board Certified in Psychiatry matthewfelgusmd.com
More informationOpioid Dependence and Buprenorphine Management
Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale
More informationDeveloped and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services
Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationDisclosure Statement. Learning Objectives. American Psychiatric Nurses Association. Christian J. Teter, PharmD, BCPP 1 BUPRENORPHINE UPDATE
BUPRENORPHINE UPDATE Christian J. Teter, Pharm.D., BCPP Associate Professor, Psychopharmacology College Of Pharmacy, University Of New England Portland, ME E-Mail: cteter@une.edu Image Source: pubchem.ncbi.nlm.nih.gov
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationMEDICATION ASSISTED TREATMENT
MEDICATION ASSISTED TREATMENT MODULE 14 ALLIED TRADES ASSISTANCE PROGRAM PREVENTATIVE EDUCATION: SUBSTANCE USE DISORDER Medication Assisted Treatment Types of Medication Assisted Treatment: Methadone Naltrexone
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationImplementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018
Implementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018 Judith Martin, MD, Medical Director of Substance Use Services, San Francisco Department of Public Health Webinar
More informationHow soon does tramadol withdrawal start
Cari untuk: Cari Cari How soon does tramadol withdrawal start How to Stop Restless Legs From Opiate Withdrawal using natural remedies at home. Opiate Withdrawal Restless Legs can be eased using these powerful
More informationOpioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
More informationPatient Initiation: Buprenorphine/Naloxone
Patient Initiation: Buprenorphine/Naloxone Kristin Wason, MSN, APRN, CARN Office-Based Addiction Treatment Program Boston Medical Center *Images used for educational purposes only. All copyrights belong
More informationLA County, Medications for Addiction Treatment, and the Substance Use Care Continuum
LA County, Medications for Addiction Treatment, and the Substance Use Care Continuum Brian Hurley, M.D., M.B.A., DFASAM Medical Director of Substance Use Related Care Integration Los Angeles County Health
More informationMedication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment
Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationROSC & MAT II: Opioid Treatment Services
ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment
ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment This booklet was created to help you learn about tapering. You probably have lots
More informationPoisoning Deaths vs. Motor Vehicle Related Injury Deaths, MA Residents ( )
Source: National Vital Statistics Poisoning Deaths vs. Motor Vehicle Related Injury Deaths, MA Residents (1997 2008) The source of the data is: Registry of Vital Records and Statistics, MA Department of
More information8/28/2017. Headlines. How Did We Get Here? Pain is the number one reason patients go the doctors office, urgent care and/or emergency room.
Ashel Kruetzkamp, MSN, RN, SANE Headlines How Did We Get Here? Pain is the number one reason patients go the doctors office, urgent care and/or emergency room. Opiates are the most effective pain medication
More informationPrescription Opioid Addiction
CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett
More informationSW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
More informationBuprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
More informationWhat Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
More informationLatest Press Release. How much for 30 mg adderall
corp@stantec.com Latest Press Release How much for 30 mg adderall S 14-2-2008 Hi my name is Rachel i have been on suboxone for almost a year as of OCT 1st, and I have become the person I guess I am to
More informationOpioid dependence: Detoxification
Opioid dependence: Detoxification What is detoxification? A. Process of removal of toxins from the body? B. Admitting a drug dependent person in a hospital and giving him nutrition? C. Stopping drug use
More informationUnderstanding and Combating the Heroin Epidemic
Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the
More informationOPIOID REPLACEMANT THERAPY: AN OVERVIEW
OPIOID REPLACEMANT THERAPY: AN OVERVIEW Matthew Felgus MD FASAM Matthew A Felgus, MD, FASAM mafelgus@wisc.edu matthewfelgusmd.com 6333 Odana Rd, Ste 3, Madison WI 53719 (608) 257-1581 Board Certified in
More informationTaking the pain out of prescribing: An opioid primer for the primary care provider
Taking the pain out of prescribing: An opioid primer for the primary care provider Amy K. Paul, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds April 26, 2016 2016 MFMER slide-1 Objectives Describe
More information9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare
Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for
More informationSUBOXONE TREATMENT PROGRAM
SUBOXONE TREATMENT PROGRAM What is Suboxone? Suboxone is a medication used for the treatment of addiction to prescription pain medication, heroin addiction, methadone or other opioid dependence. The primary
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Objectives Review Full Opioid
More informationBuprenorphine Access in California
Buprenorphine Access in California James J. Gasper, PharmD, BCPP Pharmacy Benefits Division Department of Health Care Services james.gasper@dhcs.ca.gov Source: CDPH Vital Statisitics Death Statistical
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationMedication Assisted Treatment. Michael Palladini, RPh MBA CAC
Medication Assisted Treatment Michael Palladini, RPh MBA CAC palladini.michael@gmail.com History of MAT Addiction as a Disease The concept of addiction as a disease of the brain challenges deeply ingrained
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationCONSENT FOR TREATMENT WITH NALTREXONE
CONSENT FOR TREATMENT WITH NALTREXONE Oral Naltrexone (Revia) and Extended-Release Injectable Naltrexone (Vivitrol) Naltrexone is a prescription medication that is used to: Prevent relapse to opiate/opioid
More information6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder
Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of
More informationMedication Assisted Treatment. Nicole Gastala, MD
Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants
More informationTalking with your doctor
SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may
More informationOST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO
OST Pharmacology & Therapeutics Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO Disclaimer In the past two years I have received no payment for services from any agency other than government or academic.
More informationOpioid Conversions Mixture of Science and Art
Opioid Conversions Mixture of Science and Art Matthew J. Pingree, MD Assistant Professor Division of Pain Medicine Physical Medicine and Rehabilitation and Anesthesiology Mayo Clinic, Rochester Pingree.Matthew@Mayo.edu
More informationBuprenorphine Toolkit
Buprenorphine Toolkit Selected Practice Tools: Daily Use in Clinical Practice Sample Primary Care Clinic Guidelines for Buprenorphine Rx... 1 DSM-5 Criteria for Opiate Disorders Worksheet... 3 Outpatient
More informationSource: National Vital Statistics
Summarize the basics of how to wean patients off of opiates and who is at risk of withdrawal. Review the signs and symptoms of withdrawal from chronic opioids. Summarize how providers can use medications
More informationOpiate Dependency bka Opioid Addiction
Opiate Dependency bka Opioid Addiction GP CME Dunedin July 2012 Doug Sellman Professor of Psychiatry and Addiction Medicine Director, National Addiction Centre University of Otago, Christchurch What this
More informationOpioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W.
Opioid Use Disorders as a Brain Disease Why MAT is so important Ron Jackson, M.S.W., L.I.C.S.W. Affiliate Professor School of Social Work University of Washington Organization Name: CareOregon Course Title:
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationOverview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University
More information2/21/2018. What are Opioids?
Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting
More informationFREQUENTLY ASKED QUESTIONS PATIENTS SUBOXONE (buprenorphine HCl/naloxone HCl dihydrate) sublingual tablet
463142 State Road 200, Yulee, Florida 32097 Phone: 904-225-8280 Fax: 904-225-8232 FREQUENTLY ASKED QUESTIONS PATIENTS SUBOXONE (buprenorphine HCl/naloxone HCl dihydrate) sublingual tablet 1. Why do I have
More informationMedications for Addiction Treatment in the Mental Health and Physical Health Sectors
Medications for Addiction Treatment in the Mental Health and Physical Health Sectors Brian Hurley, M.D., M.B.A., DFASAM Medical Director of Substance Use Related Care Integration Los Angeles County Health
More informationMANAGING OPIOID WITHDRAWAL AND OPIOID USE DISORDER (OUD)
MANAGING OPIOID WITHDRAWAL AND OPIOID USE DISORDER (OUD) Michelle Meyer, PharmD, BCPS, BCNSP Andrea Wetshtein, PharmD, BCPS,CPE OhioHealth Grant Medical Center OBJECTIVES Pharmacist Learning Objectives
More informationGuidelines for Community Detoxification using Buprenorphine.
Subject Title NHS Fife Community Health Partnerships Addiction Services Guidelines for Community Detoxification using Buprenorphine. Intranet Procedure No A3 Author Dr A Baldacchino Copy No 3 Reviewer
More informationMAT in the Corrections Setting
MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on
More informationMedication-Assisted Treatment (MAT) for Opioid Use Disorders
Medication-Assisted Treatment (MAT) for Opioid Use Disorders Sybil Marsh MA MD FASAM Department of Family Medicine and Community Health Case Western Reserve University/UHCMC Learning Objective 1 Following
More informationOpioids. Sergio Hernandez, MD
Opioids Sergio Hernandez, MD Required Slide Disclosures 1. SIGNIFICANT FINANCIAL INTERESTS NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT 2. GENERAL AND OBLIGATION INTERESTS All general
More informationModule 6: Overview Opioid Dependence Treatment with Buprenorphine/Naloxone
Module 6: Overview Opioid Dependence Treatment with Buprenorphine/Naloxone History of Medical Practice for Opioid Addiction in the U.S. Physicians had been liberal prescribers of morphine in late 1800s/early
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationOpioid Overdose Epidemic A Crises and Opportunity
Opioid Overdose Epidemic A Crises and Opportunity Samuel M. Silverman MD, FAPA, DFASAM Assistant Clinical Professor, UConn Medical School Director, Medical Education Rushford, A Hartford HealthCare Partner
More informationMedication Assisted Treatment:
Medication Assisted Treatment: A Training For Multidisciplinary Addiction Professionals Module III Medications 101 Goals for Module III This module reviews the following: Overview of three medications
More information12/14/2018. Disclosures. Buprenorphine. Drug-Receptor Interactions. Affinity
ECHO Ontario Chronic Pain Bootcamp OPIOID CHALLENGE Buprenorphine/Naloxone: What and How? Friday, December 7, 2018 Disclosures Presenters: John Flannery & Andrew Smith Conflicts of Interest: None John
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationDisclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.
Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of
More informationBuprenorphine treatment
South London and Maudsley NHS Foundation Trust Buprenorphine treatment Information for service users Page Buprenorphine treatment What is buprenorphine? Buprenorphine (trade name Subutex ) is an opioid
More informationMedical Assisted Treatment of Opioid
Medical Assisted Treatment of Opioid Dependence with XR-NTX(Vivitrol) Michael McNamara DO, FACN Medical Director Mental Health Center of Greater Manchester Manchester NH Outline Overview of Opioid Dependence
More informationTreating Opioid Addiction
Treating Opioid Addiction Some people who start taking opioid pain medications eventually have serious problems with them and become addicted. Every day, 68 people die in the US from opioid overdose. More
More informationVivitrol Drug Court and Medication Assisted Treatment
Vivitrol Drug Court and Medication Assisted Treatment Amy Black, CNP and Judge Fred Moses Court program Self-starters Mission Statement To provide court-managed, medically assisted drug intervention treatment
More informationManagement of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
More informationSUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION
SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place
More informationRationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers
Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers Marwan S. Haddad, M.D. Community Health Center, Inc. Connecticut September 16, 2008 Community Health Center, Inc.
More informationMAT 101: TREATMENT OF OPIOID USE DISORDER
MAT 101: TREATMENT OF OPIOID USE DISORDER WITH SPECIAL EMPHASIS ON BUPRENORPHINE/NALOXONE ICADD May 22, 2018 Alicia Carrasco, MD Debby Woodall, LCSW, ACADC Magni Hamso, MD, MPH Terry Reilly Health Services
More informationOverview of Opioid Use Disorder
Overview of Opioid Use Disorder Doug Burgess, MD Medical Director of Outpatient Services, Truman Medical Centers Assistant Professor of Psychiatry, University of Missouri- Kansas City Objectives History
More informationIdentification and Treatment of Opioid Use Disorders in Primary Care Settings
Identification and Treatment of Opioid Use Disorders in Primary Care Settings 17th Annual Primary Care Symposium February 24, 2018 Kelly S. Barth, DO Associate Professor, Psychiatry & Internal Medicine
More informationPPT-PGN-26 Part of NTW(C)38-Pharmacological therapies
Pharmacological therapies - Practice Guidance Note Guidance for the in-patient use of opiate substitution therapy.v01 Date Issued Issue 1 Jun 2018 Planned Review Jun 2021 PPT-PGN-26 Part of NTW(C)38-Pharmacological
More informationMEDICALLY ASSISTED TREATMENT IN PROBLEMATIC OPIOID Punta Cana 2018
MEDICALLY ASSISTED TREATMENT IN PROBLEMATIC OPIOID USE @joelbordman Punta Cana 2018 Copyright 2017 by Sea Courses Inc All rights reserved. No part of this document may be reproduced, copied, stored, or
More information